Reuters
The shares of CureVac, a German biotechnology company subsidized through Bill Gates, rose 18% in pre-market operations Thursday after the company announced it in talks with the European Commission to supply doses of its possible coronavirus vaccine.
The possible contract with the European Commission aims to provide EU member states with up to 225 million doses of the coronavirus vaccine, once it has been demonstrated and effectively opposes COVID-19, the corporation said in a press release.
The contract would also give the European Commission the option to purchase 180 million more doses, bringing the total to 405 million doses of the vaccine.
If an agreement is reached, it would mark the company’s first bilateral agreement, according to Reuters.
CureVac’s mND-based COVID-19 candidate vaccine is recently undergoing a Phase 1 clinical trial at various sites in Germany and Belgium for the protection and efficacy of the drug in humans, the company said. Expect to offload the effects of the test in the early fourth quarter of 2020 and move on to the next phase within a while.
CureVac has earned more than 255% from its debut in the inventory market until the close of Wednesday.
Market Insider